Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 4/20 | 0.71 |
| ▸ | NPY4R | P50391 | 4/20 | 0.71 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.71 |
| ▸ | NPY1R | P25929 | 3/20 | 0.71 |
| ▸ | MC4R | P32245 | 1/20 | 0.68 |
| ▸ | MC5R | P33032 | 1/20 | 0.68 |
| ▸ | MC3R | P41968 | 1/20 | 0.68 |
| ▸ | MC1R | Q01726 | 1/20 | 0.68 |
| ▸ | CXCR4 | P61073 | 6/20 | 0.68 |
| ▸ | GLP1R | P43220 | 5/20 | 0.67 |
| ▸ | CALCA | P06881 | 1/20 | 0.65 |
| ▸ | RAMP3 | O60896 | 1/20 | 0.64 |
| ▸ | CALCR | P30988 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29599666 | 0.94 | GLP1R (0.70) | NPY2RNPY4RNPY5RNPY1RGLP1R | |
| SCHEMBL29351953 | 0.93 | NPY2R (0.74) | NPY2RNPY4RNPY5RNPY1RMC4R | |
| SCHEMBL31060386 | 0.91 | CALCA (0.75) | NPY2RNPY4RNPY5RNPY1RCXCR4 | |
| SCHEMBL29360268 | 0.90 | NPY1R (0.74) | NPY2RNPY4RNPY5RNPY1RMC4R | |
| Acetic Acid SCHEMBL29399515 | 0.90 | NPY1R (0.75) | NPY2RNPY4RNPY5RNPY1RMC4R | |
| SCHEMBL29355231 | 0.90 | NPY1R (0.76) | NPY2RNPY4RNPY5RNPY1RMC4R | |
| SCHEMBL29367990 | 0.89 | CALCA (0.69) | NPY2RNPY4RNPY5RNPY1RMC4R | |
| SCHEMBL29464565 | 0.89 | CXCR4 (0.66) | NPY2RNPY4RNPY5RNPY1RMC4R | |
| SCHEMBL29598077 | 0.89 | NPY2R (0.75) | NPY2RNPY4RNPY5RNPY1RGLP1R | |
| Tosactide SCHEMBL29353880 | 0.89 | MC4R (0.77) | NPY2RNPY4RNPY5RNPY1RMC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110101840-B | Application of combination of neuropeptide B23/W23 and morphine in preparation of analgesic drugs | 徐州医科大学 | 2023-03-28 | — | — | CN | claimed |
| US-20260049331-A1 | Sense-and-Response of Proteins, Peptides, and Small Molecules Using Ligand-Induced Dimerization Activating RNA Editing (LIDAR) | UNIV LELAND STANFORD JUNIOR (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4149556-B1 | PEG LIPIDOID COMPOUNDS | TRANSLATE BIO INC (US) | 2026-01-07 | — | — | EP | disclosed |
| US-12514932-B2 | PEG lipidoid compounds | TRANSLATE BIO, INC. (US) | 2026-01-06 | — | — | US | disclosed |
| US-12453759-B2 | Di-thioester cationic lipids | TRANSLATE BIO, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| EP-4618957-A1 | COMPOSITIONS COMPRISING OCTADECANEUROPEPTIDES (ODN) AND SYNTHETIC DERIVATIVES THEREOF AND METHODS OF USE FOR MODULATION OF FOOD INTAKE, OBESITY, BODY WEIGHT, NAUSEA, AND EMESIS | The Trustees of The University of Pennsylvania (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20250288523-A1 | PEG LIPIDOID COMPOUNDS | TRANSLATE BIO INC (US) | 2025-09-18 | — | — | US | disclosed |
| US-20250257046-A1 | VITAMIN CATIONIC LIPIDS | TRANSLATE BIO INC (US) | 2025-08-14 | — | — | US | disclosed |
| US-20250255971-A1 | ICE-BASED LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF MRNA | TRANSLATE BIO, INC. | 2025-08-14 | — | — | US | disclosed |
| EP-3621632-B1 | ANTIMICROBIAL PEPTIDES WITH ALPHA-CORE HELICES | LOS ANGELES BIOMEDICAL RES INST HARBOR UCLA MEDICAL CT (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20220257724-A1 | DI-THIOESTER CATIONIC LIPIDS | TRANSLATE BIO, INC. | 2022-08-18 | — | — | US | disclosed |
| US-20220249699-A1 | COMPOSITIONS AND METHODS FOR mRNA DELIVERY | TRANSLATE BIO, INC. | 2022-08-11 | — | — | US | disclosed |
| US-11407837-B2 | GPCR binding proteins and synthesis thereof | Twist Bioscience Corporation (US) | 2022-08-09 | — | — | US | disclosed |
| US-20220233444-A1 | THIOESTER CATIONIC LIPIDS | TRANSLATE BIO, INC. | 2022-07-28 | — | — | US | disclosed |
| US-20220226236-A1 | Pulmonary Delivery of MRNA to Non-lung Target Cells | RANA THERAPEUTICS, INC. | 2022-07-21 | — | — | US | disclosed |
| US-20220226244-A1 | MACROCYCLIC LIPIDS | TRANSLATE BIO INC (US) | 2022-07-21 | — | — | US | disclosed |
| US-20220177423-A1 | CYSTINE CATIONIC LIPIDS | TRANSLATE BIO, INC. | 2022-06-09 | — | — | US | disclosed |
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2022-05-05 | — | — | US | disclosed |
| US-20220073944-A1 | MULTIMERIC CODING NUCLEIC ACID AND USES THEREOF | TRANSLATE BIO, INC. | 2022-03-10 | — | — | US | disclosed |
| US-20220071905-A1 | PEG LIPIDOID COMPOUNDS | TRANSLATE BIO, INC. | 2022-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | NPY2R 3500/4885NPY4R 3663/4885NPY5R 4072/4885 |
| US-20250257046-A1 | VITAMIN CATIONIC LIPIDS | APMAP, TTPA, CLN6 | NPY2R 4443/4885NPY4R 4577/4885NPY5R 4620/4885 |
| US-20220177423-A1 | CYSTINE CATIONIC LIPIDS | SLC7A11, SLC7A1, SLC7A5 | NPY2R 3556/4885NPY4R 4102/4885NPY5R 3657/4885 |
| US-20250255971-A1 | ICE-BASED LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF MRNA | CETP, SREBF2, NPC1L1 | NPY2R 3668/4885NPY4R 3435/4885NPY5R 3045/4885 |
| US-20220073944-A1 | MULTIMERIC CODING NUCLEIC ACID AND USES THEREOF | NSUN3, TRDMT1, NSUN2 | NPY2R 2426/4885NPY4R 2483/4885NPY5R 1761/4885 |
| US-20250288523-A1 | PEG LIPIDOID COMPOUNDS | LIPG, ABCB4, HDLBP | NPY2R 4234/4885NPY4R 4133/4885NPY5R 4417/4885 |
| US-12453759-B2 | Di-thioester cationic lipids | ACOT7, LYPLA2, LYPLA1 | NPY2R 4214/4885NPY4R 3883/4885NPY5R 4516/4885 |
| US-20220071905-A1 | PEG LIPIDOID COMPOUNDS | HDLBP, LIPG, ABCB4 | NPY2R 4154/4885NPY4R 4018/4885NPY5R 4436/4885 |
| US-20220233444-A1 | THIOESTER CATIONIC LIPIDS | CETP, ACOT7, LYPLA1 | NPY2R 3640/4885NPY4R 3800/4885NPY5R 3946/4885 |
| US-20220226244-A1 | MACROCYCLIC LIPIDS | SGMS1, NPC1L1, ABCB4 | NPY2R 3702/4885NPY4R 4075/4885NPY5R 4333/4885 |
| US-20220249699-A1 | COMPOSITIONS AND METHODS FOR mRNA DELIVERY | RNGTT, RNASE1, RNMT | NPY2R 4152/4885NPY4R 4230/4885NPY5R 4127/4885 |
| US-20260049331-A1 | Sense-and-Response of Proteins, Peptides, and Small Molecules Using Ligand-Induced Dimerization Activating RNA Editing (LIDAR) | ADAR, ZFR, SLIRP | NPY2R 1995/4885NPY4R 2452/4885NPY5R 2958/4885 |
| US-20220257724-A1 | DI-THIOESTER CATIONIC LIPIDS | ACOT7, LYPLA2, LYPLA1 | NPY2R 4214/4885NPY4R 3883/4885NPY5R 4516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.